Noxopharm is an Australian publicly-listed (ASX: NOX) clinical stage drug development company.
The clinical stage drug candidate is Veyonda® (previously known as NOX-66). Veyonda® is a first-in-class, dual-acting cytotoxic and immuno-oncology drug candidate designed to enhance the effectiveness and safety of both chemotherapy and radiotherapy.
At one level, Veyonda® enhances the cancer-killing effect of standard chemotherapy and radiotherapy, thereby enabling lower doses of these toxic therapies to be used.
At another level, it seeks to activate the body’s innate immune cell function to attack those cancer cells that have survived the initial treatment.
Veyonda® appears to work across the broad spectrum of cancers.
Our ultimate aim is to harness the body’s immune system to inflict damage on ALL cancer cells in the body, eradicating most, if not all cancer cells to produce long-term remission or even a curative outcome in what is known as an abscopal effect. An abscopal effect is where radiotherapy is applied to just the one lesion, and triggers a response in all other non-irradiated lesions.